Pancreatic neuroendocrine tumours (PNET) are relatively rare entities, accounting for 1–2 per cent of pancreatic neoplasms. However, rates of diagnosis have recently increased, in part due to incidental discovery on the widespread use of cross‐sectional imaging. While general consensus exists regarding the treatment of large and/or functional PNET, the management of smaller (<2 cm) asymptomatic lesions is less clear. Recent updates in staging guidelines have improved classification of high‐ and low‐risk tumours, and additional genetic analysis (e.g. Death domain‐associated protein 6 Gene, Alpha Thalassemia/Mental Retardation Syndrome X‐Linked Gene) offers the possibility of enhanced risk stratification to further guide surgical management. In patients who do ultimately require pancreatectomy, the role of minimally‐invasive surgery (laparoscopic or robotic) continues to expand.